PegBio (HKG:2565) entered into a material transfer agreement with SN BioScience, according to a Wednesday Hong Kong bourse filing.
Under the agreement, the parties will combine SN BioScience's proprietary Serinol Nucleic Acids long-acting drug delivery platform with three innovative peptide drug candidates for metabolic diseases developed by PegBio.
The parties will research formulation and long-acting delivery to evaluate the in vivo performance, pharmacokinetic characteristics and further development potential of the candidate-platform combinations.